With 2,000 sq. feet of dedicated R&D space in our state-of-the-art facility in Rochester, MN, Nucleus RadioPharma has the capacity and ability to prioritize your radiotherapy or theranostic product development, regardless of the isotope.
Research & Development
Accelerate radiopharmaceutical development and pre-clinical research in a controlled environment
- 2,000 sq. feet
of R&D space - Opened:
September 5, 2024
Innovate with confidence
We support radiopharmaceutical innovation from early-stage development through technology transfer. Our custom-designed R&D space offers innovators the opportunity to refine, test, and advance product development without the risk of cross-contamination.
With the capacity to work with any and all isotopes, regardless of their complexity, our expert team can consult on target material optimization, manage seamless radiopharmaceutical technology transfers, and more.
Development and formulation:
- Radiolabeling procedures
- Chelation of radioisotopes to antibodies, peptides, mini-proteins, and small molecules
- Specifications development
- Ensure processes and analytical methods meet regulatory requirements
- Radiopharmaceutical technology transfer
Stability program management:
- Lead formulation and analytical development for improved stability
- Drug stability testing under real-world storage and transportation conditions
- Shelf-life validation to meet regulatory and clinical requirements
Why Nucleus Radiopharma for your radiotherapy and theranostic R&D needs?
- Isotope-agnostic approach tailored to your therapeutic and diagnostic needs
- Seamless R&D-to-manufacturing transition with space dedicated to early-stage formulation and process refinement
- Regulatory-ready development with built-in quality and safety exceeding industry standards
